



Clinical trial results:

An Open-label, Long-term, Safety Study of LAsmiDltan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)

Summary

EudraCT number	2015-005674-37
Trial protocol	GB DE
Global end of trial date	20 August 2019

Results information

Result version number	v1 (current)
This version publication date	23 August 2020
First version publication date	23 August 2020

Trial information

Trial identification

Sponsor protocol code	H8H-CD-LAHL
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02565186
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Number: 16890

Notes:

Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877CTLilly,
Scientific contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 8772854559,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 August 2019
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	20 August 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

This is a prospective, randomized, open-label study in subjects with migraine who have completed the Phase 3 studies, COL MIG 301/LAHJ (NCT02439320) or COL MIG-302/LAHK (NCT02605174) or for a subset of lasmiditan-naïve subjects with migraine. The study is designed to evaluate the safety and tolerability of long-term intermittent use of lasmiditan 100 mg and of lasmiditan 200 mg, as the first dose and as a second dose, for the acute treatment of migraine. Long term efficacy will also be evaluated.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	07 October 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 2106
Country: Number of subjects enrolled	United Kingdom: 22
Country: Number of subjects enrolled	Germany: 43
Worldwide total number of subjects	2171
EEA total number of subjects	65

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	2085
From 65 to 84 years	86
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

NA

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Lasmiditan 100mg

Arm description:

Participants received oral dose of 100mg Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond within 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.

Arm type	Experimental
Investigational medicinal product name	Lasmiditan
Investigational medicinal product code	
Other name	LY573144
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received oral dose of 100 milligrams (mg) Lasmiditan given in four hours of onset of migraine attack. If the migraine did not respond with in 2 hours after first dose then a second dose was permitted with in 24 hours after first dose.

Arm title	Lasmiditan 200mg
------------------	------------------

Arm description:

Participants received oral dose of 200mg Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond with in 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.

Arm type	Experimental
Investigational medicinal product name	Lasmiditan
Investigational medicinal product code	
Other name	LY573144
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received oral dose of 100 milligrams (mg) Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond with in 2 hours after first dose then a second dose was permitted with in 24 hours after first dose.

Number of subjects in period 1	Lasmiditan 100mg	Lasmiditan 200mg
Started	1046	1125
Received at least one dose of study drug	991	1039
Completed	466	504
Not completed	580	621
Non-Compliance	57	55
Consent withdrawn by subject	229	214
Physician decision	18	16
Did Not Receive Study Drug	55	86
Adverse event, non-fatal	113	148
Lost to follow-up	102	93
Sponsor Request	5	9
Missing	1	-

Baseline characteristics

Reporting groups

Reporting group title	Lasmiditan 100mg
-----------------------	------------------

Reporting group description:

Participants received oral dose of 100mg Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond within 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.

Reporting group title	Lasmiditan 200mg
-----------------------	------------------

Reporting group description:

Participants received oral dose of 200mg Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond with in 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.

Reporting group values	Lasmiditan 100mg	Lasmiditan 200mg	Total
Number of subjects	1046	1125	2171
Age categorical Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous Units: years			
arithmetic mean	42.5	43.4	
standard deviation	± 12.25	± 12.33	-
Gender categorical Units: Subjects			
Female	882	957	1839
Male	164	166	330
Unknown	0	2	2
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	208	240	448
Not Hispanic or Latino	833	880	1713
Unknown or Not Reported	5	5	10
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	4	11	15
Asian	7	6	13
Native Hawaiian or Other Pacific Islander	4	6	10
Black or African American	203	194	397
White	805	884	1689

More than one race	11	14	25
Unknown or Not Reported	12	10	22
Region of Enrollment Units: Subjects			
United States	1041	1065	2106
United Kingdom	5	38	43
Germany	0	22	22

End points

End points reporting groups

Reporting group title	Lasmiditan 100mg
Reporting group description: Participants received oral dose of 100mg Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond within 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.	
Reporting group title	Lasmiditan 200mg
Reporting group description: Participants received oral dose of 200mg Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond with in 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.	

Primary: Number of participants with at least 1 Treatment Emergent Adverse Event

End point title	Number of participants with at least 1 Treatment Emergent Adverse Event ^[1]
End point description: An AE with an onset on or within 48 hours after a dose of study drug, or an event that worsened in intensity within 48 hours of a dose of study drug was considered a treatment-emergent adverse event (TEAE). A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, were reported in the Reported Adverse Events module. Analysis Population Description (APD): All randomized participants who received at least one dose of study drug.	
End point type	Primary
End point timeframe: Up to 12 months	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Per protocol, Statistical comparisons were not planned for this endpoint.	

End point values	Lasmiditan 100mg	Lasmiditan 200mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	991	1039		
Units: Participants				
number (not applicable)	447	545		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Migraine attacks with Pain Freedom (PF) at 2 hours after dose

End point title	Percentage of Migraine attacks with Pain Freedom (PF) at 2 hours after dose
-----------------	---

End point description:

Pain freedom is defined as a reduction in headache severity from mild (1), moderate (2), or severe (3) at baseline to none (0).

APD: All randomized participants who treated at least 1 qualifying migraine attack within 4 hours of onset.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 12 months

End point values	Lasmiditan 100mg	Lasmiditan 200mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	954 ^[2]	1000 ^[3]		
Units: Percentage of PF Migraine Attacks				
number (not applicable)	26.7	32.2		

Notes:

[2] - Total Migraine Attacks: 8837

[3] - Total Migraine Attacks: 8479

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Migraine Attacks With Most Bothersome Symptom-Free (MBS) at 2 Hours After Dose

End point title	Percentage of Migraine Attacks With Most Bothersome Symptom-Free (MBS) at 2 Hours After Dose
-----------------	--

End point description:

MBS-free, defined as the absence of the associated symptom of migraine (nausea, phonophobia, and/or photophobia) at 2 hours postdose that was identified predose as the most bothersome symptom.

APD: All randomized participants who treated at least 1 qualifying migraine attack within 4 hours of onset.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 12 months

End point values	Lasmiditan 100mg	Lasmiditan 200mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	954 ^[4]	1000 ^[5]		
Units: Percentage of MBS-Free Migraine Attacks				
number (not applicable)	37.2	40.5		

Notes:

[4] - Total Migraine Attacks: 8045

[5] - Total Migraine Attacks: 7529

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Percentage of Participants with Medical Resource Utilization

End point title	Percentage of Participants with Medical Resource Utilization
-----------------	--

End point description:

Medical Resource utilization for any cardiovascular events and/or related resource utilization, such as visits to cardiologists, procedures, hospitalizations, new treatments or treatment adjustments for CV disease and any visits to an emergency room (ER) or physician's office for treatment of migraine was reported.

APD: All randomized participants who received at least one dose of study drug.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Up to 12 months

End point values	Lasmiditan 100mg	Lasmiditan 200mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	991	1039		
Units: Percentage of Participants				
number (not applicable)				
Visit to cardiologist	0.6	0.6		
Visit to primary care	0.8	0.9		
Visit to Other providers	0.1	0.2		
Hospitalized	0.5	0.2		
Procedures performed	0.8	0.6		
ER visits or visits to Physicians Office	2.6	2.6		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 12 Months

Adverse event reporting additional description:

All randomized participants who received at least one dose of study drug.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.1
--------------------	------

Reporting groups

Reporting group title	Lasmiditan 100mg
-----------------------	------------------

Reporting group description:

Participants received oral dose of 100mg Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond within 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.

Reporting group title	Lasmiditan 200mg
-----------------------	------------------

Reporting group description:

Participants received oral dose of 200mg Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond with in 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.

Serious adverse events	Lasmiditan 100mg	Lasmiditan 200mg	
Total subjects affected by serious adverse events			
subjects affected / exposed	29 / 991 (2.93%)	36 / 1039 (3.46%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
adenocarcinoma of colon			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
non-small cell lung cancer			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
thyroid cancer recurrent			

alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
hypertension			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	3 / 991 (0.30%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
hypertensive urgency			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			
abortion spontaneous			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed ^[1]	3 / 845 (0.36%)	1 / 887 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
abortion threatened			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed ^[2]	0 / 845 (0.00%)	1 / 887 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
non-cardiac chest pain			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	2 / 991 (0.20%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast			

disorders			
endometriosis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed ^[3]	0 / 845 (0.00%)	1 / 887 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
haemorrhagic ovarian cyst			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed ^[4]	0 / 845 (0.00%)	1 / 887 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ovarian cyst			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed ^[5]	0 / 845 (0.00%)	1 / 887 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
bronchospasm			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pharyngeal swelling			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
pulmonary embolism			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
upper airway obstruction			

alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
anxiety			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
depression			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
drug abuse			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
mental status changes			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
obsessive-compulsive disorder			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
schizoaffective disorder bipolar type			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
suicidal ideation			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
suicide attempt			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
femur fracture			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
head injury			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
intentional overdose			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	2 / 1039 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
skin laceration			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
subdural haematoma			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
suture rupture			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
angina pectoris			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
atrial fibrillation			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
atrial flutter			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
bradycardia			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
sinus node dysfunction			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
stress cardiomyopathy			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
hypoesthesia			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ischaemic stroke			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
relapsing-remitting multiple sclerosis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
seizure			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
transient ischaemic attack			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
gastritis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	2 / 1039 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
gastrointestinal haemorrhage			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
hiatus hernia			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	2 / 1039 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
obstructive pancreatitis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
small intestinal obstruction			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	0 / 991 (0.00%)	2 / 1039 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
cholecystitis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
cholecystitis acute			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
cholelithiasis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
gallbladder disorder			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
acute kidney injury			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
nephrolithiasis			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	0 / 991 (0.00%)	2 / 1039 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
urinary incontinence			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
intervertebral disc protrusion			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
lumbar spinal stenosis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
abscess limb			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
appendicitis perforated			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
bronchitis			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
carbuncle			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cellulitis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	2 / 991 (0.20%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
coccidioidomycosis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
diverticulitis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
pneumonia			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	2 / 1039 (0.19%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
sepsis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

sinusitis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
subcutaneous abscess			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
urinary tract infection			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Lasmiditan 100mg	Lasmiditan 200mg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	446 / 991 (45.01%)	543 / 1039 (52.26%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
benign breast neoplasm			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
cholesteatoma			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
skin papilloma			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
uterine leiomyoma			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed ^[6]	1 / 845 (0.12%)	0 / 887 (0.00%)	
occurrences (all)	1	0	
Vascular disorders			
flushing			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	3 / 1039 (0.29%)	
occurrences (all)	1	4	
hot flush			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	3 / 991 (0.30%)	4 / 1039 (0.38%)	
occurrences (all)	3	5	
hypertension			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	2 / 1039 (0.19%)	
occurrences (all)	1	2	
hypotension			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
orthostatic hypotension			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
pallor			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
peripheral coldness			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
asthenia			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	15 / 991 (1.51%)	24 / 1039 (2.31%)	
occurrences (all)	38	48	
chest discomfort			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	3 / 991 (0.30%)	4 / 1039 (0.38%)	
occurrences (all)	64	8	
chills			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	3 / 1039 (0.29%)	
occurrences (all)	0	3	
discomfort			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	3 / 1039 (0.29%)	
occurrences (all)	1	3	
facial pain			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	2	
fatigue			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	47 / 991 (4.74%)	64 / 1039 (6.16%)
occurrences (all)	90	159
feeling abnormal		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	7 / 991 (0.71%)	8 / 1039 (0.77%)
occurrences (all)	11	9
feeling cold		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)
occurrences (all)	1	3
feeling drunk		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	2 / 1039 (0.19%)
occurrences (all)	3	4
feeling hot		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	3 / 1039 (0.29%)
occurrences (all)	0	3
feeling jittery		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	7 / 991 (0.71%)	5 / 1039 (0.48%)
occurrences (all)	9	11
feeling of relaxation		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)
occurrences (all)	2	9
gait disturbance		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	4 / 1039 (0.38%)
occurrences (all)	3	6
hunger		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0

influenza like illness		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)
occurrences (all)	1	1
injection site erythema		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
injection site swelling		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
malaise		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	3 / 991 (0.30%)	2 / 1039 (0.19%)
occurrences (all)	5	3
non-cardiac chest pain		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	4 / 1039 (0.38%)
occurrences (all)	2	4
oedema		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
oedema peripheral		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
pyrexia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)
occurrences (all)	1	1
swelling face		
alternative dictionary used: MedDRA 22.1		

subjects affected / exposed occurrences (all)	1 / 991 (0.10%) 1	2 / 1039 (0.19%) 3	
Immune system disorders seasonal allergy alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	0 / 991 (0.00%) 0	2 / 1039 (0.19%) 2	
Reproductive system and breast disorders breast pain alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all) dysmenorrhoea alternative dictionary used: MedDRA 22.1 subjects affected / exposed ^[7] occurrences (all) menstruation irregular alternative dictionary used: MedDRA 22.1 subjects affected / exposed ^[8] occurrences (all)	1 / 991 (0.10%) 1 0 / 845 (0.00%) 0 1 / 845 (0.12%) 1	0 / 1039 (0.00%) 0 1 / 887 (0.11%) 1 0 / 887 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders aphonia alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all) cough alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all) dyspnoea alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all) epistaxis alternative dictionary used:	0 / 991 (0.00%) 0 0 / 991 (0.00%) 0 3 / 991 (0.30%) 3	1 / 1039 (0.10%) 1 3 / 1039 (0.29%) 21 3 / 1039 (0.29%) 3	

MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)	
occurrences (all)	1	1	
nasal odour			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
oropharyngeal pain			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
paranasal sinus discomfort			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
respiratory depression			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
rhinitis allergic			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	2 / 991 (0.20%)	0 / 1039 (0.00%)	
occurrences (all)	2	0	
sinus congestion			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
throat tightness			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
Psychiatric disorders			
abnormal dreams			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	4 / 991 (0.40%)	6 / 1039 (0.58%)
occurrences (all)	8	23
affect liability		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	2	0
agitation		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	1 / 1039 (0.10%)
occurrences (all)	3	2
anxiety		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	8 / 991 (0.81%)	9 / 1039 (0.87%)
occurrences (all)	12	9
attention deficit/hyperactivity disorder		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
bipolar disorder		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
confusional state		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	3 / 1039 (0.29%)
occurrences (all)	0	3
depersonalisation/derealisation disorder		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
depressed mood		
alternative dictionary used: MedDRA 22.1		

subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
depression		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	4 / 991 (0.40%)	3 / 1039 (0.29%)
occurrences (all)	4	3
disorientation		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	8 / 1039 (0.77%)
occurrences (all)	0	11
dysphoria		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	3 / 1039 (0.29%)
occurrences (all)	1	3
emotional distress		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
enuresis		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)
occurrences (all)	1	1
euphoric mood		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	5 / 991 (0.50%)	11 / 1039 (1.06%)
occurrences (all)	7	22
fear		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
hallucination		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	5 / 991 (0.50%)	3 / 1039 (0.29%)
occurrences (all)	5	3

hallucination, auditory		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
hallucination, visual		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
hypnagogic hallucination		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
insomnia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	5 / 991 (0.50%)	7 / 1039 (0.67%)
occurrences (all)	5	10
irritability		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)
occurrences (all)	1	1
listless		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
major depression		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
mental fatigue		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
mood swings		
alternative dictionary used: MedDRA 22.1		

subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
nervousness			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
nightmare			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	3 / 1039 (0.29%)	
occurrences (all)	2	7	
panic attack			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	3 / 1039 (0.29%)	
occurrences (all)	0	3	
phonophobia			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
restlessness			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	6 / 991 (0.61%)	5 / 1039 (0.48%)	
occurrences (all)	7	6	
sleep disorder			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)	
occurrences (all)	1	1	
suicidal ideation			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
Investigations			
aspartate aminotransferase increased			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
blood creatinine increased		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	0 / 1039 (0.00%)
occurrences (all)	2	0
blood glucose increased		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
blood phosphorus decreased		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
blood pressure decreased		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	2 / 1039 (0.19%)
occurrences (all)	0	3
blood pressure diastolic increased		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
blood pressure increased		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	2 / 1039 (0.19%)
occurrences (all)	2	2
blood triglycerides increased		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	2 / 1039 (0.19%)
occurrences (all)	0	2
electrocardiogram t wave biphasic		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1

haematocrit decreased		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
heart rate decreased		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	2 / 1039 (0.19%)
occurrences (all)	0	2
heart rate increased		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	1 / 1039 (0.10%)
occurrences (all)	2	1
heart rate irregular		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
hepatic enzyme increased		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
norovirus test positive		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
urine analysis abnormal		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
weight increased		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
white blood cells urine positive		
alternative dictionary used: MedDRA 22.1		

subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
Injury, poisoning and procedural complications			
animal bite			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)	
occurrences (all)	1	1	
arthropod bite			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
contusion			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	2 / 991 (0.20%)	2 / 1039 (0.19%)	
occurrences (all)	4	2	
eye injury			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
foot fracture			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
hand fracture			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
joint dislocation			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
ligament rupture			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
ligament sprain			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	4 / 991 (0.40%)	0 / 1039 (0.00%)	
occurrences (all)	4	0	
limb injury			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
maternal exposure during pregnancy			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed ^[9]	1 / 845 (0.12%)	0 / 887 (0.00%)	
occurrences (all)	1	0	
muscle strain			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
road traffic accident			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	2 / 991 (0.20%)	0 / 1039 (0.00%)	
occurrences (all)	2	0	
skin abrasion			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
skin laceration			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
Cardiac disorders			
bundle branch block left			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
palpitations			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	3 / 991 (0.30%)	5 / 1039 (0.48%)	
occurrences (all)	6	5	
tachycardia			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	2 / 1039 (0.19%)	
occurrences (all)	0	3	
Nervous system disorders			
akathisia			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	2 / 991 (0.20%)	2 / 1039 (0.19%)	
occurrences (all)	3	24	
altered state of consciousness			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
aphasia			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
ataxia			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	3 / 991 (0.30%)	7 / 1039 (0.67%)	
occurrences (all)	11	31	
aura			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
balance disorder			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	7 / 991 (0.71%)	19 / 1039 (1.83%)
occurrences (all)	21	31
cognitive disorder		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	4 / 991 (0.40%)	3 / 1039 (0.29%)
occurrences (all)	5	4
coordination abnormal		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	3 / 1039 (0.29%)
occurrences (all)	0	4
disturbance in attention		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	6 / 1039 (0.58%)
occurrences (all)	2	9
dizziness		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	156 / 991 (15.74%)	220 / 1039 (21.17%)
occurrences (all)	336	647
dysarthria		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	2 / 1039 (0.19%)
occurrences (all)	0	2
dysgeusia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
dyskinesia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)
occurrences (all)	1	1
fine motor skill dysfunction		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	3 / 1039 (0.29%)
occurrences (all)	0	5

head discomfort		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	5 / 1039 (0.48%)
occurrences (all)	1	7
headache		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	3 / 991 (0.30%)	5 / 1039 (0.48%)
occurrences (all)	3	5
hypersomnia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	1 / 1039 (0.10%)
occurrences (all)	2	2
hypoesthesia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	13 / 991 (1.31%)	21 / 1039 (2.02%)
occurrences (all)	16	31
lethargy		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	20 / 991 (2.02%)	14 / 1039 (1.35%)
occurrences (all)	36	34
medication overuse headache		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
memory impairment		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	2 / 1039 (0.19%)
occurrences (all)	2	3
mental impairment		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
migraine		
alternative dictionary used: MedDRA 22.1		

subjects affected / exposed	9 / 991 (0.91%)	9 / 1039 (0.87%)
occurrences (all)	10	9
mononeuropathy		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
neuralgia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
neuropathy peripheral		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
paraesthesia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	53 / 991 (5.35%)	86 / 1039 (8.28%)
occurrences (all)	84	293
parosmia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
psychomotor hyperactivity		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
restless legs syndrome		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	5 / 991 (0.50%)	4 / 1039 (0.38%)
occurrences (all)	8	5
sciatica		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	0 / 1039 (0.00%)
occurrences (all)	2	0

sedation		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	3 / 991 (0.30%)	5 / 1039 (0.48%)
occurrences (all)	9	7
sensory disturbance		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	2
sinus headache		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
sleep paralysis		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
somnolence		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	77 / 991 (7.77%)	95 / 1039 (9.14%)
occurrences (all)	153	290
speech disorder		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
stupor		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
syncope		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	2 / 1039 (0.19%)
occurrences (all)	0	2
tarsal tunnel syndrome		
alternative dictionary used: MedDRA 22.1		

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>tension headache</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>tremor</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>visual field defect</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 991 (0.10%)</p> <p>2</p> <p>0 / 991 (0.00%)</p> <p>0</p> <p>8 / 991 (0.81%)</p> <p>8</p> <p>2 / 991 (0.20%)</p> <p>2</p>	<p>0 / 1039 (0.00%)</p> <p>0</p> <p>2 / 1039 (0.19%)</p> <p>2</p> <p>14 / 1039 (1.35%)</p> <p>19</p> <p>2 / 1039 (0.19%)</p> <p>2</p>	
<p>Blood and lymphatic system disorders</p> <p>anaemia</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>lymphadenopathy</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 991 (0.20%)</p> <p>2</p> <p>0 / 991 (0.00%)</p> <p>0</p>	<p>1 / 1039 (0.10%)</p> <p>1</p> <p>1 / 1039 (0.10%)</p> <p>1</p>	
<p>Ear and labyrinth disorders</p> <p>diplacusis</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>ear discomfort</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>ear pain</p> <p>alternative dictionary used: MedDRA 22.1</p>	<p>0 / 991 (0.00%)</p> <p>0</p> <p>0 / 991 (0.00%)</p> <p>0</p>	<p>1 / 1039 (0.10%)</p> <p>1</p> <p>1 / 1039 (0.10%)</p> <p>5</p>	

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>0 / 991 (0.00%)</p> <p>0</p>	<p>1 / 1039 (0.10%)</p> <p>1</p>	
<p>hypoacusis</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 991 (0.10%)</p> <p>1</p>	<p>0 / 1039 (0.00%)</p> <p>0</p>	
<p>tinnitus</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>4 / 991 (0.40%)</p> <p>4</p>	<p>4 / 1039 (0.38%)</p> <p>5</p>	
<p>vertigo</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>10 / 991 (1.01%)</p> <p>15</p>	<p>24 / 1039 (2.31%)</p> <p>53</p>	
<p>Eye disorders</p> <p>altered visual depth perception</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>0 / 991 (0.00%)</p> <p>0</p>	<p>1 / 1039 (0.10%)</p> <p>1</p>	
<p>blindness transient</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 991 (0.10%)</p> <p>1</p>	<p>0 / 1039 (0.00%)</p> <p>0</p>	
<p>cataract</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 991 (0.10%)</p> <p>1</p>	<p>0 / 1039 (0.00%)</p> <p>0</p>	
<p>conjunctivitis allergic</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>0 / 991 (0.00%)</p> <p>0</p>	<p>1 / 1039 (0.10%)</p> <p>1</p>	
<p>dyschromatopsia</p> <p>alternative dictionary used: MedDRA 22.1</p>		

subjects affected / exposed	0 / 991 (0.00%)	2 / 1039 (0.19%)
occurrences (all)	0	2
eye disorder		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	3
iritis		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
metamorphopsia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	3 / 1039 (0.29%)
occurrences (all)	0	3
miosis		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
papilloedema		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
photophobia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	2 / 1039 (0.19%)
occurrences (all)	0	2
photopsia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	3 / 991 (0.30%)	5 / 1039 (0.48%)
occurrences (all)	3	6
strabismus		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1

vision blurred alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	2 / 991 (0.20%) 2	6 / 1039 (0.58%) 8	
visual impairment alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	3 / 991 (0.30%) 7	8 / 1039 (0.77%) 23	
vitreous floaters alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	0 / 991 (0.00%) 0	2 / 1039 (0.19%) 2	
Gastrointestinal disorders abdominal discomfort alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	1 / 991 (0.10%) 1	5 / 1039 (0.48%) 5	
abdominal distension alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	2 / 991 (0.20%) 2	0 / 1039 (0.00%) 0	
abdominal hernia alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	1 / 991 (0.10%) 1	0 / 1039 (0.00%) 0	
abdominal pain alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	2 / 991 (0.20%) 2	1 / 1039 (0.10%) 1	
abdominal pain lower alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	0 / 991 (0.00%) 0	1 / 1039 (0.10%) 2	
abdominal pain upper alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	1 / 991 (0.10%)	3 / 1039 (0.29%)
occurrences (all)	1	3
dental caries		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
diarrhoea		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	10 / 991 (1.01%)	6 / 1039 (0.58%)
occurrences (all)	10	12
dyspepsia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
epigastric discomfort		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
food poisoning		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
frequent bowel movements		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
gastritis		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	2 / 1039 (0.19%)
occurrences (all)	0	2
gastrointestinal inflammation		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1

gastrooesophageal reflux disease		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	2 / 1039 (0.19%)
occurrences (all)	1	2
hiatus hernia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
hypoaesthesia oral		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	2 / 1039 (0.19%)
occurrences (all)	1	3
irritable bowel syndrome		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
nausea		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	39 / 991 (3.94%)	55 / 1039 (5.29%)
occurrences (all)	47	81
oral pain		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)
occurrences (all)	1	1
paraesthesia oral		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	4 / 991 (0.40%)	1 / 1039 (0.10%)
occurrences (all)	4	1
retching		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)
occurrences (all)	1	1
swollen tongue		
alternative dictionary used: MedDRA 22.1		

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>0 / 991 (0.00%)</p> <p>0</p>	<p>1 / 1039 (0.10%)</p> <p>1</p>	
<p>tooth disorder</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 991 (0.10%)</p> <p>1</p>	<p>0 / 1039 (0.00%)</p> <p>0</p>	
<p>toothache</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>0 / 991 (0.00%)</p> <p>0</p>	<p>1 / 1039 (0.10%)</p> <p>1</p>	
<p>vomiting</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>17 / 991 (1.72%)</p> <p>18</p>	<p>11 / 1039 (1.06%)</p> <p>12</p>	
<p>Hepatobiliary disorders</p> <p>cholecystitis</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 991 (0.10%)</p> <p>1</p>	<p>0 / 1039 (0.00%)</p> <p>0</p>	
<p>cholelithiasis</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>0 / 991 (0.00%)</p> <p>0</p>	<p>2 / 1039 (0.19%)</p> <p>2</p>	
<p>sphincter of oddi dysfunction</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 991 (0.10%)</p> <p>1</p>	<p>0 / 1039 (0.00%)</p> <p>0</p>	
<p>Skin and subcutaneous tissue disorders</p> <p>acne</p> <p>alternative dictionary used: MedDRA 22.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>0 / 991 (0.00%)</p> <p>0</p>	<p>1 / 1039 (0.10%)</p> <p>1</p>	
<p>actinic keratosis</p> <p>alternative dictionary used: MedDRA 22.1</p>		

subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
alopecia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
blister		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
dermatitis		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
dermatitis contact		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
hyperhidrosis		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	4 / 1039 (0.38%)
occurrences (all)	2	5
ingrown hair		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
night sweats		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
pruritus		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	1 / 1039 (0.10%)
occurrences (all)	5	1

rash alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	3 / 991 (0.30%) 3	1 / 1039 (0.10%) 1	
rash papular alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	0 / 991 (0.00%) 0	1 / 1039 (0.10%) 1	
seborrhoeic dermatitis alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	0 / 991 (0.00%) 0	1 / 1039 (0.10%) 1	
skin burning sensation alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	1 / 991 (0.10%) 2	0 / 1039 (0.00%) 0	
skin mass alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	0 / 991 (0.00%) 0	1 / 1039 (0.10%) 1	
urticaria alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	1 / 991 (0.10%) 1	0 / 1039 (0.00%) 0	
Renal and urinary disorders calculus bladder alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	0 / 991 (0.00%) 0	1 / 1039 (0.10%) 1	
haematuria alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	1 / 991 (0.10%) 1	0 / 1039 (0.00%) 0	
hypertonic bladder alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)	
occurrences (all)	1	1	
nephrolithiasis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)	
occurrences (all)	1	1	
proteinuria			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
renal pain			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal and connective tissue disorders			
arthralgia			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	3 / 991 (0.30%)	3 / 1039 (0.29%)	
occurrences (all)	3	3	
back pain			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	5 / 991 (0.50%)	6 / 1039 (0.58%)	
occurrences (all)	5	6	
bursitis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
exostosis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
fibromyalgia			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
foot deformity		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
joint instability		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
ligament laxity		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
limb discomfort		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	9 / 1039 (0.87%)
occurrences (all)	12	17
limb mass		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
muscle fatigue		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
muscle spasms		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	6 / 991 (0.61%)	6 / 1039 (0.58%)
occurrences (all)	7	8
muscle twitching		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	5 / 991 (0.50%)	7 / 1039 (0.67%)
occurrences (all)	6	12

muscular weakness		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	9 / 991 (0.91%)	16 / 1039 (1.54%)
occurrences (all)	23	49
musculoskeletal chest pain		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	2 / 1039 (0.19%)
occurrences (all)	1	2
musculoskeletal stiffness		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	2 / 1039 (0.19%)
occurrences (all)	1	3
myalgia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
neck pain		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	1 / 1039 (0.10%)
occurrences (all)	2	1
pain in extremity		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	1 / 1039 (0.10%)
occurrences (all)	2	1
plantar fasciitis		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
rotator cuff syndrome		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	2 / 1039 (0.19%)
occurrences (all)	0	2
spinal osteoarthritis		
alternative dictionary used: MedDRA 22.1		

subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
tendonitis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)	
occurrences (all)	1	1	
trigger finger			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
Infections and infestations			
acute sinusitis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
atypical pneumonia			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
bacterial vaginosis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed ^[10]	0 / 845 (0.00%)	1 / 887 (0.11%)	
occurrences (all)	0	1	
body tinea			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
bronchitis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	2 / 991 (0.20%)	3 / 1039 (0.29%)	
occurrences (all)	2	3	
campylobacter gastroenteritis			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
conjunctivitis		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
fungal skin infection		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
furuncle		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
gastroenteritis		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	2 / 1039 (0.19%)
occurrences (all)	0	2
gastroenteritis viral		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
gingivitis		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
herpes zoster		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	3 / 1039 (0.29%)
occurrences (all)	2	3
influenza		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	4 / 1039 (0.38%)
occurrences (all)	2	4

labyrinthitis		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
lyme disease		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
nasopharyngitis		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	4 / 991 (0.40%)	9 / 1039 (0.87%)
occurrences (all)	4	9
otitis externa		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)
occurrences (all)	1	1
otitis media acute		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
pharyngitis		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)
occurrences (all)	1	1
pharyngitis streptococcal		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	2 / 991 (0.20%)	2 / 1039 (0.19%)
occurrences (all)	2	2
pneumonia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	2 / 1039 (0.19%)
occurrences (all)	0	2
rhinitis		
alternative dictionary used: MedDRA 22.1		

subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
sinusitis			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	4 / 991 (0.40%)	8 / 1039 (0.77%)	
occurrences (all)	4	8	
tooth abscess			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	1 / 1039 (0.10%)	
occurrences (all)	1	1	
upper respiratory tract infection			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	10 / 991 (1.01%)	6 / 1039 (0.58%)	
occurrences (all)	10	6	
upper respiratory tract infection bacterial			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)	
occurrences (all)	1	0	
urinary tract infection			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	5 / 991 (0.50%)	5 / 1039 (0.48%)	
occurrences (all)	5	5	
viral infection			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	2 / 991 (0.20%)	1 / 1039 (0.10%)	
occurrences (all)	2	1	
Metabolism and nutrition disorders			
decreased appetite			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)	
occurrences (all)	0	1	
dehydration			
alternative dictionary used: MedDRA 22.1			

subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
hypercholesterolaemia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 991 (0.00%)	1 / 1039 (0.10%)
occurrences (all)	0	1
hypoglycaemia		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
obesity		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	0 / 1039 (0.00%)
occurrences (all)	1	0
type 2 diabetes mellitus		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	2 / 1039 (0.19%)
occurrences (all)	1	2
vitamin d deficiency		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 991 (0.10%)	3 / 1039 (0.29%)
occurrences (all)	1	3

Notes:

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.

[8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.

[9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.

[10] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
12 May 2017	-revised definition of study completion -extended enrollment interval between open label and feeder studies
15 September 2017	Deletion of discontinuation criteria
09 April 2018	Subjects should not exceed a total dose of 200 mg of Lasmiditan in a 24-hour period. Subjects randomized to Lasmiditan 100 mg will be allowed to take a second dose of study drug if needed for recurrence of migraine.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported